Administration errors of compounded semaglutide reported to a poison control center—Case series
Abstract
Background We aimed to increase pharmacists' and regulatory agencies' awareness of emerging issues regarding current practices of semaglutide use in the community that has led to increased reports of administration errors and adverse drug events to our regional poison control center.Case summary We report 3 cases of adverse drug events after incorrect administration of semaglutide for weight loss obtained from compounding pharmacies and an aesthetic spa. Two patients self-administered 10-fold dosing errors. All patients experienced notable symptoms of nausea, vomiting, and abdominal pain with most symptoms lasting for days. Other symptoms of headache, anorexia, weakness, and fatigue were reported in one patient. One patient sought evaluation at a health care facility and responded well to an antiemetic and intravenous fluids. One patient who received their medication from a compounding pharmacy reported receiving a vial with syringes for self-administration; no pharmacist counseling was provided on proper drug administration. One patient reported dosing in milliliters and units rather than in milligrams.Practice implications These 3 semaglutide cases highlight the potential for patient harm given current practices. Vials of compounded semaglutide do not use safety features provided by prefilled manufactured pens and allow for large overdoses (e.g., 10-fold dosing errors). Use of syringes not intended for semaglutide contributes to the variability of dosing units (milliliters, units, milligrams), contributing to patient confusion. To address such issues, we encourage increased vigilance in labeling, dispensing, and counseling practices to ensure patients are confident in administering their medication regardless of the formulation. We additionally encourage boards of pharmacy and other regulatory agencies to promote proper use and dispensing of compounded semaglutide. Such vigilance and promotion could decrease the risk of more severe adverse drug events and avoidable hospital utilization that may arise from dosing errors.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Users' alterations in alcohol consumption and substance use following initiation of semaglutide 2.4 mg contribute to existing literature supporting GLP-1RA as a potential treatment approach for addiction.
“Users have also noted alterations in alcohol consumption and substance use following the initiation of semaglutide 2.4 mg, contributing to the existing body of literature supporting GLP‐1RA as a potential treatment approach for addiction [21, 23, 26, 27].”
From A Qualitative Analysis of Patient Experiences Using Semaglutide 2.4 mg for Weight Loss (2025) · cites this paper as [26]
A significant number of concerning reports regarding safety and efficacy of compounded incretin products have emerged, including use of unproven salt forms, untested additional ingredients, nonstandard concentrations and doses, and counterfeit products.
“A significant number of concerning reports regarding safety and efficacy of compounded incretin products have emerged, however, including using salt forms of the FDA-approved product's active ingredient that are not proven safe or effective for use in humans, incorporation of additional ingredients not clinically tested when mixed with incretin products (e.g., vitamin B12 and vitamin B6), products”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [208]
Cites
A method for estimating the probability of adverse drug reactions
Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Janecek, E., Domecq, C., & Greenblatt, D. J. (1981) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1981.154 · Cited by 11,914 · see citing works
Aroda, V. R., Erhan, U., Jelnes, P., Meier, J. J., Abildlund, M. T., Pratley, R. E., Vilsbøll, T., & Husain, M. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14990 · Cited by 55 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s009 · Cited by 728 · see citing works
GLP-1 agonists: A review for emergency clinicians
Long, B., Pelletier, J., Koyfman, A., & Bridwell, R. E. (2024) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2024.01.010 · Cited by 67 · see citing works
Neumiller, J. J., Bajaj, M., Bannuru, R. R., McCoy, R. G., Pekas, E. J., Segal, A. R., & ElSayed, N. A. (2025) · Diabetes Care · doi:10.2337/dci24-0091 · Cited by 49 · see citing works
A Qualitative Analysis of Patient Experiences Using Semaglutide 2.4 mg for Weight Loss
Plenn, E., Amin, D., Henry, J., Leavitt, G., Walker, J., & Soleymani, T. (2025) · Obesity Science & Practice · doi:10.1002/osp4.70085 · Cited by 8 · see citing works
“Users have also noted alterations in alcohol consumption and substance use following the initiation of semaglutide 2.4 mg, contributing to the existing body of literature supporting GLP‐1RA as a potential treatment approach for addiction [21, 23, 26, 27].”
Influential
- Authors
- Lambson, J. E., Flegal, S. C., & Johnson, A. R.
- Affiliations
- University of Utah (US)
- Corresponding author
- Lambson, Joseph E.
- ORCID
- Lambson, Joseph E.
- Venue
- Journal of the American Pharmacists Association
- Publisher
- Elsevier BV
- Published
- 2023-09
- Volume
- 63
- Issue
- 5
- Pages
- 1643-1645
- ISSN
- 1544-3191 (ISSN-L)
- OpenAlex
- W4382518402
- Cited by
- 40
- References
- 2
- Citations by year
- 2026: 11 · 2025: 13 · 2024: 14 · 2023: 2
- FWCI
- 13.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of the American Pharmacists Association (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Health Professions › Emergency Medical Services › Patient Safety and Medication Errors
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacy and Medical Practices
- Health Sciences › Medicine › Emergency Medicine › Poisoning and overdose treatments
- Keywords
- semaglutide, compounded medications, medication administration errors, dosing errors, adverse drug reactions, poison control center reports, anti-obesity drugs, self-administration, compounding pharmacies, drug labeling, pharmacist counseling, regulatory oversight, nausea and vomiting
- MeSH terms
- Semaglutide, Pharmaceutical Preparations, Humans, Medication Errors, Pharmacists, Poison Control Centers, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review